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SUMMARY
Toll-like receptors (TLRs) activate distinct, yet over-
lappingsets of signalingmolecules, leading to inflam-
matory responses to pathogens. Toll/interleukin-1
receptor (TIR) domains, present in all TLRs and TLR
adapters, mediate protein interactions downstream
of activated TLRs. A peptide library derived from
TLR2 TIR was screened for inhibition of TLR2 sig-
naling. Cell-permeable peptides derived from the D
helix and the segment immediately N-terminal to the
TLR2 TIR domain potently inhibited TLR2-mediated
cytokine production. The D-helix peptide, 2R9, also
potently inhibited TLR4, TLR7, and TLR9, but not
TLR3 or TNF-a signaling. Cell imaging, co-immuno-
precipitation, and in vitro studies demonstrated that
2R9preferentially targetsTIRAP.2R9diminishedsys-
temic cytokine responses elicited in vivo by synthetic
TLR2 and TLR7 agonists; it inhibited the activation of
macrophages infected with influenza strain A/PR/8/
34 (PR8) and significantly improved the survival of
PR8-infected mice. Thus, 2R9 represents a TLR-tar-
geting agent that blocks protein interactions down-
stream of activated TLRs.
INTRODUCTION
Toll-like receptors (TLRs) recognize exogenous microbial and
endogenous damage-associated molecules to activate inflam-
matory responses critical for host recovery from infection or
sterile tissue injury (Chen and Nun˜ez, 2010; Kawai and Akira,
2011). Ligand interaction with TLR ectodomains induces dimer-
ization of cytoplasmic Toll/interleukin-1 receptor (TIR) domains
of two receptor molecules (Jin and Lee, 2008). This creates
composite binding sites, to which adaptor proteins are re-
cruited through TIR domains present in each TLR adaptor, lead-
ing to the activation of several signaling cascades (Gay et al.,
2014). In mammals, TIR domains are present in all TLRs, inter-
leukin-1R (IL-1R) family members, and the adapters that trans-
duce signals from these receptors (Gay and Keith, 1991;
Medzhitov et al., 1997; O’Neill and Bowie, 2007). TIR domains
are protein interaction domains that mediate transient interac-
tions of signaling proteins. TIR domains tend to interact with
other TIR domains; nevertheless, no common TIR:TIR binding
motif has been identified (Pawson and Nash, 2003; Toshchakov
and Vogel, 2007). TLRs and the proteins that transduce TLR sig-
nals are important therapeutic targets because excessive or
prolonged TLR activation underlies many chronic inflammatory
diseases and might be lethal (Brandes et al., 2013; Kawai and
Akira, 2011; O’Neill et al., 2009).
TLR2 is activated by many ligands specific to Gram-positive
bacteria, mycobacteria, or fungi (Means et al., 1999; Takeuchi
et al., 1999; Underhill et al., 1999; Werts et al., 2001). TLR2 func-
tions as a heterodimer with TLR1 or TLR6 and activates the
MyD88-dependent signaling leading to activation of nuclear
factor kB (NF-kB) and production of proinflammatory cytokines
(Ozinsky et al., 2000). TLR2 utilizes two TIR domain-containing
adapters: MyD88 and TIRAP, also called Mal. MyD88 is an
adaptor common to all human TIR-containing receptors, except
TLR3, whereas TIRAP participates in fewer pathways (Kawai and
Akira, 2010; Medzhitov et al., 1998). Early experiments demon-
strated that cells obtained from TIRAP-deficient mice are hypo-
responsive to TLR4 and TLR2 ligands but capable of mounting a
potent response to TLR3, TLR5, TLR7, and TLR9 agonists
(Horng et al., 2002; Yamamoto et al., 2002). Later studies elabo-
rated that the responsiveness of TIRAP-deficient cells to TLR2
agonists could be partly restored by prolonged exposure to a
pathogen or increased agonist concentration (Cole et al., 2010;
Kenny et al., 2009). Another study has found that, analogously
to its role in TLR2 signaling, TIRAP facilitates TLR9 signaling
because the TLR9 response is severely diminished by a targeted
mutation of the TIRAP gene in some cell types, as is the response
to several viral pathogens (Bonham et al., 2014).
Although the general mechanism by which TLR activation in-
duces formation of cytoplasmic signaling complexes has been
determined, the specific location of sites that mediate the in-
teractions of TIR-containing proteins in a functional signaling
complex, as well as the composition and stoichiometry of
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components in the immediate receptor complexes, is still
debated (Gay et al., 2014 for a recent review; see Piao et al.,
2013a and Enokizono et al., 2013 for an example of debate). Pre-
viously, we screened several libraries of peptides derived from
putative TIR:TIR interaction sites of TLR4 and TIR-containing
TLR4 adapters and identified several as potent TLR inhibitors
that competitively block TIR:TIR interactions required for signal
transduction (Couture et al., 2012; Piao et al., 2013a, 2013b;
Toshchakov et al., 2011).
The present study extends our prior work by identification of
a TLR2-derived peptide, 2R9, which is a potent, multispecific
TLR inhibitor that inhibits cytokine activation elicited by TLR2,
TLR4, TLR7, and TLR9 agonists. A cell-based fluorescence
resonance energy transfer (FRET) assay and co-immunoprecip-
itation studies demonstrated that 2R9 primarily targets TIRAP;
however, a weak binding of 2R9 to TLR4 and TLR7 was also
detected. We analyzed 2R9/TIRAP interaction by using recombi-
nant TIRAP, which revealed that 2R9 binds TIRAP with nanomo-
lar affinity as a result of a fast association rate coupled with slow
dissociation of the complex. 2R9 binds albumin with micromolar
affinity. 2R9 potently inhibits cytokine production by cultured
macrophages infected with the mouse-adapted influenza virus
strain A/PR/8/34 (PR8) and protects mice from lethal PR8
challenge.
RESULTS
Screening of TLR2 Peptide Library
TLR2 activation leads to a direct interaction of the TLR2 TIR
domain with the TIR domain of TLR1 or TLR6, followed by
recruitment of TIRAP and MyD88, to the dimer, through TIR
domains of these adapters. Therefore, TLR2 TIR participates
in several TIR:TIR interactions, each of which might be
competitively blocked by a peptide derived from a TLR2 TIR
interface, leading to diminished signaling (Toshchakov and Vo-
gel, 2007). To identify TLR2 inhibitors, we designed a library of
cell-permeable TLR2-derived peptides and tested individual
peptides for the ability to block TLR2-mediated signaling in
primary mouse macrophages. All decoy peptide sequences
were synthesized fused to the translocating segment of the
Antennapedia homeodomain (RQIKIWFQNRRMKWKK) at the
N terminus (Derossi et al., 1994). Eleven peptides, named
2R1–2R11, each of which represents a separate patch of
TLR2 TIR surface, were examined in the primary screening
(Figure S1).
We first tested whether the peptides inhibit cytokine mRNA
transcription induced by S-[2,3-bis(palmitoyloxy)-(2-RS)-pro-
pyl]-N-palmitoyl-(R)-Cys-Ser-Lys4-OH (P3C), a synthetic lipo-
peptide that activates the TLR2/TLR1 heterodimer (Ozinsky
et al., 2000), and by S-[2,3-bis-(palmitoyloxy)-(2-RS)-propyl]-
[R]-Cys-Ser-Lys4-OH (P2C) or Fibroblast-Stimulating Lipopep-
tide-1 (FSL-1), two lipopeptides recognized by the TLR2/TLR6
heterodimer (Takeuchi et al., 2001). Two peptides, 2R1 and
2R9, potently inhibited tumor necrosis factor alpha (TNF-a) and
IL-1b mRNA expression 1 hr after macrophage stimulation with
P3C, whereas the third peptide, 2R3, inhibited suboptimally (Fig-
ure 1A). 2R1 and 2R9 also potently inhibited mRNA induced
by TLR2/TLR6 agonists, P2C, or FSL-1 (Figures 1B and 1C).
Although 2R4 did not inhibit TLR2 significantly (Figures 1A–1F),
we confirmed our previous data (Toshchakov et al., 2007) that
2BB, a peptide that represents the extended BB loop of TLR2
and includes all 2R4 residues, inhibits the P3C-induced cytokine
production in macrophages (Figure S2).
In accordance with strong effects of 2R1 and 2R9 on cytokine
expression, both peptides potently inhibited phosphorylation of
IKK-a/b, kinases of the NF-kB activation pathway, induced by
all TLR2 agonists (Figures 1D–1G). The inhibitory effect on
MAPK activation, however, was limited to TLR2/TLR1 signaling:
2R1 and 2R9 inhibited ERK and JNK induced by P3C, a TLR2/
TLR1 agonist but failed to inhibit activation of MAPKs induced
by P2C or FSL-1, thus suggesting a distinct mechanism of
MAPK activation via TLR2/TLR1 and TLR2/TLR6 (Figures 1D–
1G). 2R1 and 2R9 potently inhibited TNF-a and IL-6 secretion
measured in macrophage supernatants 5 or 24 hr after stimula-
tion by all TLR2 agonists, indicating that peptides exert a long-
lasting inhibitory effect (Figures 1H–1J). To determine the effect
of peptides on cell viability, we conducted 3-[4,5-dimethylthia-
zol-2-yl]-2,5 diphenyltetrazolium bromide (MTT) incorporation
assay. Macrophage viability was consistently greater than 80%
for all peptides, at all conditions, and, in particular, 2R1 and
2R9 exerted a minimal effect on cell viability that was compara-
ble to the effect on cell viability caused by P3C stimulation alone
(Figure S3). The negative effect of TLR2 activation on cell
viability, particularly by P3C, has long been reported and is
attributed to pro-apoptotic properties of TLR2 agonists (Alipran-
tis et al., 1999).
We examined whether inhibitory peptides derived frommouse
TLR2 inhibit human TLR2 and found that effects of both peptides
are highly similar in human andmousemacrophages (Figure S4).
Thus, we identified two TLR2 inhibitory peptides that block
TLR2-mediated responses in vitro by 80%–90% in human and
mouse cells, with minimal effects on cell viability.
Specificity of Signaling Inhibition by TLR2-Derived
Peptides
TLR2-derived peptides that inhibited TLR2 were next examined
for inhibition of signaling induced by TNF-a, TLR4, TLR7, TLR9,
and TLR3. 2R1, but not 2R9, inhibited TNF-a and IL-1b mRNA
expression induced by TNF-a (Figures 2A and 2B), suggesting
that 2R1 might target a protein that does not have a TIR domain.
Peptides 2R9 and 2R1, but not the control peptide (CP), also
potently decreased TLR4-induced TNF-a and IL-1b expression
(data not shown) and secretion (Figures 2C and 2D). R848, an
imidazoquinoline compound that activates TLR7 (Diebold
et al., 2004; Heil et al., 2004; Lund et al., 2004), and ODN1668,
a class B CpG oligonucleotide that activates murine TLR9,
induced robust production of TNF-a and IL-6 by cultured murine
macrophages (Figures 2E and 2F). Treatment of cells with 2R9 at
20 mM, the lower effective dose used in Figure 1, decreased
TLR7 and TLR9-activated cytokine production by 75%–80%
(Figures 2E and 2F). 2R9 did not affect the interferon b (IFN-b)
secretion and STAT-1 activation induced by the TLR3 agonist,
poly(I:C) (Figures 2G and 2H). Thus, the inhibitory effects of
2R1 are non-specific in contrast to those of 2R9, which does
not block TNF-a- or TLR3-mediated signaling but blocks TLR2,
TLR4, TLR7, and TLR9.
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2R9 Binds TIRAP and Prevents Adaptor Recruitment to
TLR2 Signaling Complex
The specificity profile exhibited by 2R9 could either be a con-
sequence of targeting several distinct TIR domains or result
from targeting one TIR-containing adaptor, common to several
TLRs. To identify TIR domains targeted by 2R9, we used two
approaches. The first is that a panel of fluorescently labeled
TIR-containing proteins, each a candidate binding partner for
2R9, is expressed in a host cell line, and the resulting cell lines
are treated with a decoy peptide labeled with a fluorescent dye
that can serve as a FRET acceptor for the TIR label. If a peptide
binds the TIR domain, it results in FRET and an associated
decrease in donor fluorescence lifetime. Cerulean (Cer)-labeled
TIR domains and Bodipy-TMR-X (BTX)-labeled decoy peptides
were used as a FRET pair to study interactions of decoy peptides
with TIR domains (Toshchakov et al., 2011). We recently devel-
oped a Fluorescence Lifetime IMaging (FLIM)-based approach
that enables quantitative comparisons of TIR-peptide binding af-
finities directly in cells (Szmacinski et al., 2014). This approach
was used to analyze new FLIM images. The second approach
Figure 1. Peptides 2R1 and 2R9 Inhibit TLR2-Mediated Macrophage Activation
(A–C) Effect of TLR2 decoy peptides on cytokine mRNA expression. Mouse peritoneal macrophages were treated with 20 or 40 mM of indicated peptides for
30 min prior to stimulation with P3C (500 ng/ml) (A), P2C (50 ng/ml) (B), or FSL-1 (50 ng/ml) (C). Cytokine mRNA was measured 1 hr after cell stimulation and is
normalized to the expression of HPRT.
(D–G) IKKa/b and MAPK phosphorylation was measured by western blot in lysates of macrophages stimulated with a TLR2 agonist for indicated duration.
(H–J) TNF-a and IL-6 contents in macrophage supernatants 5 (open columns, scaled by left Y axes) or 24 hr (black columns, right Y axes) after P3C (I), P2C (H), or
FSL-1 (J) stimulation of mock- or peptide-treated macrophages. Peptides (40 mM) were added 30 min before TLR2 stimulation. BD, below detection limit.
Data in each panel represent at least three independent experiments. Numerical data are presented as means ± SEM. See also Figures S1–S3.
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that was developed to analyze TIR-peptide binding is the dot blot
immunoprecipitation assay, in which labeled TIR domains are
expressed in cells and then immunoprecipitated from cell lysates
spiked with decoy peptides. In this approach, the level of pep-
tide-TIR binding is estimated by quantifying peptides in immuno-
precipitates (Piao et al., 2013a).
Upon TLR2 activation, TLR2 TIR dimerizes with the TIR
domain of TLR1 or TLR6 and the dimer recruits TIRAP and
MyD88 through TIR domains of these adapters. Therefore,
TLR1, MyD88, and TIRAP TIR domains were selected as the pri-
mary candidate targets of TLR2-derived decoy peptides, and
mammalian expression vectors that encode these TIR domains
fused at the C terminus with Cer were generated. Figures 3A–
3C present results of analysis of Cer fluorescence lifetime in im-
ages of HeLa cells transfected with Cer-fused, TIR-containing
proteins and incubated in the presence of different concentra-
tions of BTX-labeled 2R9 (BTX-2R9) for 1 hr. Images were
analyzed with the bi-exponential fluorescence decay model
with the fixed components’ lifetimes of 2.96 ns (free donor) and
0.9 ns (donor-acceptor pair), determined as described previ-
ously (Szmacinski et al., 2014). Figure 3A demonstrates cell im-
ages in pseudocolor based on the fractional amplitude of the
short lifetime component, a1; this parameter reflects the portion
of acceptor-bound donormolecules (Szmacinski et al., 2014). In-
cubation of TIRAP-Cer-expressing cells with BTX-2R9 caused a
significant, dose-dependent increase of a1, reflecting the higher
molecular fraction of donor-acceptor pairs. This finding indicates
a direct interaction between TIRAP and 2R9. The selective
quenching of TIRAP-Cer fluorescence by BTX-2R9 is clearly
visible in the a1 images of cells treated with 10 or 50 mM of 2R9
as shown by pseudocolor (Figure 3A) and by the appearance
of distinct peaks at high a1 values in histograms of Figure 3B.
Formation of donor-acceptor pairs in the presence of 2R9 was
considerably less for the TLR1-expressing cells and less yet
for the MyD88-expressing cells (Figures 3A–3C). Importantly,
Cer not fused with a TIR domain was not quenched to a com-
parable degree even by the highest concentration of BTX-2R9
used (Figure 3C), indicating that 2R9 indeed targets TIRAP in
the TIRAP-Cer fusion protein.
FLIM images of cells incubated at varied concentrations of
2R9 were used to estimate the apparent TIR-2R9 binding affin-
ities in cellular milieu. The titration plots (Figure 3C) were con-
structed under the assumption that amplitude a1 corresponds
to the molecular fraction of donor-acceptor pairs as a1 = [DA] /
([D] + [DA]). At each acceptor concentration, the a1 values in Fig-
ure 3C correspond to the predominant pixel frequency derived
from several images by using histograms such as the one in Fig-
ure 3B. Fitting the experimental points with logistic function
revealed that mid-points are at 3.8, 109.2, and 1055.3 mM for
TIRAP, TLR1, and MyD88, respectively. The >10-fold higher af-
finity of 2R9 binding to TIRAP in comparison to TIRAP binding
to TLR1 or MyD88 suggests that 2R9 selectively binds TIRAP.
Figure 2. Specificity of TLR Inhibition by TLR2-Derived Peptides
(A andB) Effect of TLR2 peptides on TNF-induced cytokine expression.Mouse peritonealmacrophageswere treatedwith 40 mM (black bars) or 20 mM (open bars)
of indicated peptides for 30 min prior to stimulation with TNF-a (10 ng/ml). Cells were lysed 1 hr after stimulation.
(C–G) Effect of peptides on cytokine secretion induced in primary macrophages by LPS (100 ng/ml) (C and D), R848 (2.85 mM) and ODN1668 (1 mM) (E and F), or
poly(I:C) (PIC) (50 mg/ml) (G).
(H) Macrophage extracts were analyzed for STAT1-Y701 phosphorylation by western blot.
CP, control peptide. Numerical data are presented as means ± SEM. See also Figure S4.
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The apparent affinity of 2R9/TIRAP binding in cells is in the low
micromolar range and thus corresponds to the effective 2R9
dose for signaling inhibition and suggests that 2R9/TIRAP bind-
ing might account for TLR inhibition by this peptide.
Co-immunoprecipitation studies confirmed the robust 2R9/
TIRAP binding and indicated that 2R9 binds TIRAPmore strongly
than other TLR2-derived inhibitory peptides (Figure 3D). The
binding of 2R9 to the MyD88 TIR domain, however, was much
weaker compared to that of 2R1 or TR6, a TIRAPC helix peptide,
the strong binding of which to the MyD88 TIR domain was previ-
ously reported (Couture et al., 2012; Piao et al., 2013a). 2R9
binding to TLR1 and TLR6 was weaker than that for two other
TLR2 peptides (Figures S5A and S5B); however, we noted
considerable binding of 2R9 to TLR4 (Figure S5C). 2R9/TLR4
binding was only slightly less than that of 4BB, a TLR4-derived
peptide that strongly binds TLR4 (Szmacinski et al., 2014; Tosh-
chakov et al., 2011). Interestingly, regions of TIR surface repre-
sented by 2R1 and 2R3 peptides are juxtaposed (Figure S1B),
Figure 3. 2R9 Binding Specificity
(A) The fractional amplitude of the short lifetime component in FLIM images of cells transfected with TIRAP-Cer (upper row), TLR1-Cer (middle row), and MyD88
TIR-Cer (bottom row) and treated with 10 or 50 mM of BTX-2R9.
(B) Distribution of fractional amplitude of the short lifetime component in FLIM images of BTX-2R9-treated HeLa cells that express TIRAP-Cer, TLR1-Cer, or
MyD88-Cer.
(C) Concentration dependence of the apparent molecular fraction of acceptor-bound TIR domains for TIRAP-Cer-, TLR1-Cer-, or MyD88-Cer-expressing HeLa
cells. The molecular fractions were calculated from characteristic amplitudes of lifetime components in images of cells incubated with different acceptor con-
centrations.
(D) Peptide-TIR co-immunoprecipitation. Lysates of HEK293T cells that express indicated fusion proteins were incubated with 20 mM of indicated peptides for
1 hr and immunoprecipitated with anti-eCFP Ab. Peptide contents in the immunoprecipitates were measured by the dot blot assay using Ab to Antennapedia
translocating sequence (Antp). Peptides TR6, MR4, and 4BB were used as a positive binding control for MyD88, TIRAP, and TLR4, respectively. See also
Figure S5.
(E) 2R9 decreases co-immunoprecipitation of activated TLR2 with TLR2 adapters. Primary peritoneal macrophages were treated with 40 mMof indicated peptide
for 30 min prior to treatment with a TLR2 agonist. 500 mg of cell lysates was immunoprecipitated by anti-TLR2 Ab, and the immune complex was assessed with
anti-TIRAP or anti-MyD88 Ab. Data represent three individual experiments.
(F) FP analysis of 2R9 protein binding. 2R9 binds TIRAP with high affinity. BTX-labeled peptides were dissolved in PBS at 50 nM and titrated with recombinant
mouse TIRAP or BSA.
(G) 2R9/TIRAP SPR single cycle sensorgrams. Mouse TIRAP at concentrations of 21, 43, 86, 178, and 344 mMwas injected to flow cells with immobilized 2R9 or
control Antennapedia peptide in the presence or absence of BME.
Numerical data are presented as means ± SEM.
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and both peptides preferentially interact with TLR2 co-receptors,
TLR1 and TLR6. These observationsmight indicate the TLR2 TIR
interface that mediates interaction with co-receptors.
Dot blot analysis suggested a weak interaction of 2R9 with the
TLR4 TIR domain (Figure S5C); therefore, we sought to evaluate
binding of 2R9 to TIR domains of other TLRs inhibited by 2R9 and
generated expression vectors encoding Cer-labeled TLR4,
TLR7, and TLR9 TIR domains. Analysis of 2R9 binding to these
proteins was complicated by significant differences in cellular
abundance of these proteins after ectopic expression in HeLa
or HEK293T cells. Particularly, the TLR7-TIR-Cer abundance
2 days post-transfection was not sufficient for FLIM. Apparently,
cells quickly eliminated the TLR7 TIR encoding vector because
shortening of time between transfection and treatment of cells
with 2R9-BTX from 2 to 1 day resulted in better Cer expression
and fluorescent signals sufficient for FLIM (Figures S5D–S5F).
Analysis of several independently obtained images suggested
that there was detectable binding of 2R9 to TLR7 and TLR4 (Fig-
ures S5D and S5E), which was approximately ten times weaker
than 2R9-TIRAP binding (Figure S5F). We detected no binding
between 2R9 and TLR9 TIR (Figures S5D–S5G).
In accordance with the strong effect of 2R9 on TLR2 signaling,
2R9 decreased agonist-induced recruitment of both TIRAP and
MyD88 to TLR2 in co-immunoprecipitation assay (Figure 3E).
Thus, our data suggest that 2R9 suppresses TLR signaling pri-
marily through direct binding to TIRAP and a consequent indirect
effect on MyD88 recruitment; however, 2R9 might also affect
TLR4 and TLR7 signaling through weak binding to TIR domains
of these receptors.
Affinity and Kinetics of 2R9/TIRAP Binding in a Binary
System
Having identified TIRAP as the main target of the 2R9 peptide,
we next studied this interaction in vitro by using recombinant
mouse TIRAP. Two approaches were used. The first was the
fluorescence polarization assay (FP). In this assay, a fluores-
cently labeled ligand, BTX-2R9, is incubated with TIRAP and
the interaction between the two detected based on increased
polarization of ligand fluorescence due to decreased rotational
mobility of the protein-bound ligand. Figure 3F demonstrates
that BTX-2R9 fluorescence polarization (shown as fluorescence
anisotropy, r = 3P / (3P)) indeed increases dose-dependently
in the presence of recombinant TIRAP. The TIRAP-caused in-
crease in anisotropy clearly indicates direct 2R9/TIRAP binding
in solution. Fitting the observed dependence of BTX-2R9 anisot-
ropy on TIRAP concentration to the four parameter logistic func-
tion suggested the apparent KD of 2R9/TIRAP interaction is
40 nM. Incubation of BTX-labeled 2R1 in the presence of
TIRAP did not change fluorescence anisotropy, indicating that
2R9/TIRAP interaction is specific (Figure 3F). Interestingly, the
FP experiments detected binding of 2R9 to BSA, with apparent
KD in the low micromolar range (Figure 3F).
The 2R9/TIRAP interaction was studied further with the sur-
face plasmon resonance (SPR) single-cycle kinetics analysis.
The 2R9 peptide was immobilized on the surface of the flow
cell via amine coupling. As a control, the Antennapedia peptide
that contained the cell-permeating sequence of 2R9, but not
its decoy sequence, was immobilized in the control flow cell.
The SPR analysis confirmed TIRAP/2R9 interaction (Figure 3G).
The addition of reducing agent b-mercaptoethanol (BME) to
the sample buffer abolished TIRAP binding to 2R9, indicating
that TIRAP tertiary structure is important for this interaction
(Figure 3G). A notable feature of the sensorgrams is that TIRAP
binding to 2R9 has a fairly fast association rate compared to
apparently slow dissociation.
Thus, both FP and SPR analyses suggest that 2R9 specifically
binds TIRAP with high affinity. The FP experiments demon-
strated 2R9 also binds albumin with low affinity.
TLR7 Signaling Is Diminished in TIRAP-Deficient Cells
We discovered that 2R9 inhibits TLR2, TLR4, TLR7, and TLR9,
but not TLR3 (Figure 2). This specificity pattern could suggest
that 2R9 targets MyD88 because MyD88 is involved in each
blocked pathway, whereas this adaptor is dispensable for
TLR3 signaling (Kawai and Akira, 2010). However, our binding
studies demonstrated that 2R9 binds TIRAP, not MyD88 (Fig-
ure 3). The available literature only partly supports the notion
that TIRAP is involved in the pathways inhibited by 2R9. TIRAP
has long been known to be important for TLR4 and TLR2
signaling (Horng et al., 2002; Yamamoto et al., 2002). These
studies, however, suggested that TIRAP is not involved in all
MyD88-dependent TLR signaling because TIRAP-deficient
mice and cells from TIRAP-deficient mice remained capable of
responding through some TLRs, including TLR9 and TLR7. How-
ever, a more recent study specified that, although the response
to TLR9 agonists can occur in the absence of TIRAP, TIRAP fa-
cilitates the MyD88-dependent response mediated by endoso-
mal TLRs, especially in cells that are less endocytic, such as
immortalized BMDM (iBMDM) (Bonham et al., 2014). This study
also showed that TLR9 signaling and the response to viruses that
activate TLR9 and TLR7 is diminished in TIRAP-deficient cells
(Bonham et al., 2014). However, the authors did not study
whether TLR7 signaling is TIRAP dependent. We, therefore,
studied the effects of 2R9 on TLR-driven activation of wild-
type (WT) iBMDM, TIRAP-deficient iBMDMs (TIRAPKO iBMDM),
and TIRAP KO iBMDM retrovirally transfected with TIRAP (TIRAP
rescue iBMDM).
Figure 4A confirms findings of Bonham et al. that TLR9-
induced secretion of TNF-a and IL-6 in iBMDM is TIRAP-depen-
dent because TIRAP KO iBMDMs do not respond to ODN1668
(Figure 4A). This figure also demonstrates that 2R9 potently
blocks TLR9-induced production of TNF-a and IL-6 in WT
iBMDMs and in TIRAP rescue iBMDMs (Figure 4A). Figure 4B ex-
pands these findings to TLR7-mediated activation of iBMDMs.
Unlike TLR2, TLR7, or TLR9, TLR4 activates two signaling
pathways resulting in activation of a subset of genes in MyD88-
and TIRAP-independent manner (Kawai and Akira, 2010). Sur-
prisingly, the TLR4-driven activation of a MyD88- and TIRAP-in-
dependent cytokine, RANTES, was sensitive to 2R9 in iBMDM
(Figure 4C) and in peritoneal macrophages (Figure 4D), albeit
less sensitive than the genes that are completely MyD88- and
TIRAP-dependent (Figure 4E). Confirming the latter observation,
the MyD88-independent activation of STAT1, shown previously
to be the consequence of lipopolysaccharide (LPS)-induced
IFN-b acting back on themacrophages through the IFNAR (Tosh-
chakov et al., 2002), was also diminished in the presence of 2R9,
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albeit less potently than in WT macrophages (Figure 4E). These
findings likely indicate that direct binding of 2R9 to TLR4 demon-
strated by the dot blot assays and FLIM (Figures S5C–S5F)
constitutes an additional mechanism of TLR4 inhibition by this
peptide. Our data also confirm that, unlike TLR4-mediated
activation of STAT1, TLR7-mediated activation of STAT1 and
TNF-a is completely MyD88 dependent (Figures 4E and 4F).
Thus, TIRAP is important for endosomal TLR signaling through
TLR7 and TLR9, and, therefore targeting of TIRAPmight account
for the observed pattern of TLR inhibition by 2R9. Yet, binding
to additional TIR domains could also be a part of 2R9 func-
tionality given that this is most likely the case for 2R9/TLR4
and 2R9/TLR7 binding. It is noteworthy that we previously
observed that some highly inhibitory TLR-targeting decoy
peptides demonstrate similar, ‘‘multispecific’’ binding behavior.
One peptide that binds several TIR domains is TF5, a TIR-
domain-containing adapter inducing interferon-b (TRIF)-derived
TLR4 inhibitor that binds TRAM strongly and TLR4 less strongly,
whereas it does not bind MyD88 or TIRAP TIRs (Piao et al.,
2013a).
2R9 Blocks TLR2- and TLR7-Mediated Systemic
Cytokine Response in Mice
We next examined whether 2R9 is effective in vivo. C57BL/6J
mice were pretreated intraperitoneally (i.p.) with 2R9, or 2R8, a
cell-permeating peptide that does not inhibit TLRs, or TR6, a
TIRAP-derived peptide that inhibits TLR4 and TLR2 (Couture
et al., 2012), and challenged with P3C (3.3 nmol/g). Peptides
were administered at a dose of 10 nmol/g of mouse weight
1 hr before P3C. TNF-a, IL-12 p40, and IL-6 were measured in
plasma samples collected immediately before and after stimula-
tion. 2R9 pretreatment decreased the P3C-induced systemic
TNF-a levels below the limit of detection (Figure 5A). IL-12 p40
was also significantly decreased (Figure 5B). Although the
2R9-mediated IL-6 decrease was not statistically significant at
the peak time point, i.e., 2 hr after administration of P3C, the ten-
dency was there, and the P3C-induced IL-6 augmentation was
significantly lower at 4, 6, and 8 hr post-stimulation in the 2R9-
treated group (Figure 5C). TR6, a TIRAP-derived peptide that
binds MyD88 (Couture et al., 2012; Piao et al., 2013a), also
decreased the P3C-induced cytokine levels; however, the effect
of TR6 was less than that of 2R9 (Figures 5A–5C).
The effect of 2R8 and 2R9 on TLR7-induced systemic cyto-
kines was also studied. 2R9, but not the inert peptide, signifi-
cantly decreased cytokine induction by R848 (Figures 5D and
5E). These data establish 2R9 as a potent inhibitor of TLR2 and
TLR7 in vivo.
2R9 Suppresses PR8-Induced Macrophage Activation
and Protects Mice from Lethal PR8 Challenge
A broad TLR-inhibitory specificity of a candidate drug, such
as that demonstrated by 2R9, may provide a distinct advan-
tage clinically because such a compound might be expected
to modulate TLR response to pathogens, which elicit inflam-
matory responses through multiple TLRs. Influenza virus is
sensed by several innate receptors, including TLR7, TLR8,
and TLR10, and also by RIG-I, although TLR8 and TLR10 are
not functional genes in mice (Diebold et al., 2004; Heil et al.,
2004; Iwasaki and Pillai, 2014; Kawai and Akira, 2011; Lee
et al., 2014; Lund et al., 2004). Secondary TLR4 activation by
Figure 4. TIRAP Is Required for Full TLR7- and TLR9-Mediated Inflammatory Response in iBMDM
(A–C) Wild-type (WT) (open columns), TIRAP-deficient (TIRAP KO) (dashed columns), or TIRAP KO iBMDMs retrovirally transfected with TIRAP (TIRAP Rescue
iBMDM) (black columns) were pretreated with a 20 mM peptide and stimulated with (A) ODN1668 (1 mM), (B) R848 (2.85 mM), or (C) LPS (100 ng/ml). TNF-a, IL-6,
and RANTES were measured in 24-hr supernatants.
(D and E) Cytokine secretion by thioglycollate-elicited peritoneal macrophages from WT (black columns) or MyD88-deficient (MyD88KO) mice (open columns)
pretreated with 20 mM peptide and stimulated with LPS (100 ng/ml) (D) or R848 (2.85 mM) (E). Cytokine levels were measured in 24-hr supernatants.
(F) STAT-1 phosphorylation in peritoneal macrophages from WT or MyD88KO mice. Cells were stimulated as described in legend for (D) and (E) and lysed 5 hr
after stimulation.
Numerical data are presented as means ± SEM.
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endogenous ligands associated with tissue damage also plays
a significant role in influenza pathogenesis by promoting inju-
rious inflammation (Shirey et al., 2013). Therefore, we hypoth-
esized that 2R9 can modulate the innate immune response
to influenza. Cultured mouse peritoneal macrophages were
challenged in vitro with the mouse-adapted H1N1 influenza
PR8 strain at a MOI = 1 for 2 hr; then the virus was removed,
and cells were washed with PBS and mock-treated or treated
with 2R9. Cytokine levels were measured in supernatants 24 hr
later. 2R9, but not a control peptide, potently inhibited
PR8-induced secretion of TNF-a, IL-6, and IFN-b (Figures
6A–6C).
MyD88-deficient macrophages infected with PR8 induced
TNF-a and IL-6 poorly (Figures 6A and 6B), indicating a critical
contribution of TLRs to viral induction of these genes. In
contrast, the PR8-induced production of IFN-b was less
dependent on MyD88 (Figure 6C), reflecting an important
contribution of RIG-I-like receptors (RLRs) to viral induction
of type I IFNs reported for a variety of cell types (Kato et al.,
2005). Accordingly, the MyD88-independent IFN-b induction
was only slightly suppressed by 2R9 (Figure 6C). The residual
sensitivity of IFN-b expression to 2R9 reflects complexity of
immune response to live pathogens and also might be ex-
plained by indirect secondary activation of TLR4 by endoge-
nous ligands produced in response to influenza virus (Imai
et al., 2008; Shirey et al., 2013).
We next examined whether 2R9 would improve survival of
mice infected with an LD90 of PR8. Groups of PR8-infected
C57BL/6J mice received a control cell-permeating peptide, or
2R9 (200 nmol/mouse), or vehicle i.p. once daily for 5 days, start-
ing 48 hr after PR8 infection. In the 2R9-treated group, 78% of
mice survived, whereas only 12.5% and 10% survived in the
CP and vehicle control groups, respectively (p < 0.02 for both
control groups; Mantel-Cox test) (Figure 6D).
Figure 5. Effect of Inhibitory Peptides on
TLR2- and TLR7-Elicited Cytokine Activa-
tion in Mice
C57BL/6J female mice were mock-treated with
PBS or treated i.p. with 10 nmol/g of a peptide 1 hr
before i.p. administration of P3C (3.3 nmol/g) (A–C)
or R-848 (2.5 nmol/g) (D and E). Plasma samples
were obtained from six (A–C) or four (D and E)
animals. Numerical data are presented as means
± SEM. See also Figure S6.
DISCUSSION
TLRs are important therapeutic targets
because excessive or prolonged TLR
activation leads to inflammation that
can cause disease or lethality (O’Neill
et al., 2009). Due to a more significant
effort expended in the past on the devel-
opment of TLR antagonists that anta-
gonize the agonist binding sites of TLR
ectodomains, the currently available
pool of TLR inhibitors that block interac-
tions of cytoplasmic proteins is less advanced (Connolly and
O’Neill, 2012; Wang et al., 2013). Although targeting the tran-
sient protein interactions of signaling proteins is challenging
(Smith and Gestwicki, 2012), this approach could be advanta-
geous because some intracellular signaling molecules partici-
pate in several pathways or participate in a pathway in a
stoichiometrically higher quantity. Thus, broader specificity
and/or higher potency of signaling inhibition might be antici-
pated as a result of targeting a cytoplasmic signaling protein
rather than agonist antagonism.
To develop TLR inhibitors that act intracellularly by blocking
the protein interactions downstream of activated TLRs, we de-
signed and screened a library of peptides derived from putative
interaction sites of the TLR2 TIR domain, for inhibition of TLR2.
The TLR2 library is the second library derived from a receptor
TIR domain that we have examined. Originally, TLR4 peptides
were designed analogously and screened for TLR4 inhibition
(Toshchakov et al., 2011). The screening of the TLR2 library re-
vealed two peptides that potently inhibit TLR2: 2R1 corresponds
to the region that connects the TIR domain to the transmem-
brane region, whereas 2R9 represents the D helix of the TIR. Re-
gions represented by these inhibitory peptides are located at
opposite sides of the TIR domain (Figure 7A). Two other TLR2
peptides weakly suppressed TLR2, i.e., the AB loop peptide,
2R3, and the BB loop peptide (2BB), previously shown to inhibit
TLR2 and TLR4 moderately (Toshchakov et al., 2007).
Interestingly, peptides derived from structurally homologous
regions of TLR4 also inhibited signaling mediated by parent re-
ceptor (Toshchakov et al., 2011). The sequence similarity of
TLR4 and TLR2 inhibitory peptides from structurally homologous
regions is, however, rather limited. Thus, regions 1 in TLR4 and
TLR2 have only four of 14 amino acids conserved, whereas re-
gions 9 are completely dissimilar and have only one amino
acid positioned similarly, which is the central leucine, a residue
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that is completely buried in the TLR2 TIR (Figure 7B). Peptides 3
and 4 (BB) are 50% conserved in TLR2 and TLR4.
We previously reported that TLR4 peptides 4R1, 4R3, and 4BB
inhibit TLR4, bind the TLR4 TIR domain, and together form a
cluster on the TIR surface (Toshchakov et al., 2011). We pro-
posed that this cluster forms the TLR4 dimerization interface.
Interestingly, peptides from structurally homologous regions of
TLR2, i.e., 2R1, 2R3, and 2BB, also inhibit cognate receptor,
albeit 2R3 and 2BB are less potent. 2R1 binds TLR2 co-recep-
tors TLR1 and TLR6 (Figures S5A and S5B). 2R1, however, in-
hibited not only TLR2, but multiple signaling pathways; i.e., it
suppressed all TLRs tested and also TNF-a-induced signaling.
This finding might suggest that 2R1 binds several proteins with
similar affinity. Co-immunoprecipitation studies confirmed a
certain lack of specificity of 2R1 interaction with TIR domains
because significant binding of this peptide to MyD88 and both
TLR2 co-receptors was observed (Figures 3D, S5A, and S5B).
Interestingly, 4R1, the 2R1 homolog from TLR4, unlike other
TLR4 inhibitory peptides, also demonstrated ‘‘multispecific’’
binding in a cell-based FRET assay and bound both TLR4 and
TLR2 TIRs (Toshchakov et al., 2011). The BB loop is the most
conserved surface-exposed region of TIR domains (Slack
et al., 2000); e.g., BB loops of murine TLR4 and TLR2 are
50% conserved. Therefore, peptides derived from BB loop of
different proteins might be predicted to demonstrate similar
properties. Along this line, TLR4 and TLR2 BB loop peptides
were found to cross-react as each peptide suppresses both
TLR4 and TLR2 signaling (Toshchakov et al., 2007).
New and published findings suggest that TLR4 and TLR2
peptides from regions 1, 3, and 4 interact with TIR domains of
corresponding dimerization partners; yet each peptide might
have additional binding partners among TIR domains. Less spe-
cific binding to the dimerization interface in comparison to the re-
gion that mediates the recruitment of a specific protein from
cytosol might be anticipated because dimerization of receptor
TIR domains is, in a sense, a ‘‘forced’’ interaction driven by
the agonist-induced conformational change in the ectodomains.
In contrast, the adaptor recruitment site has to be specific to
function properly because binding of unrelated proteins to this
site would slow down the formation of receptor complexes.
Although the extent to which these speculations are applicable
to peptides derived from TIR:TIR interfaces is not certain at
this time, the available study suggests that the bound conforma-
tion of protein-derived peptides is often highly similar to the
conformation of the peptides in folded proteins (Vanhee et al.,
2009).
Based on observation that the D-helix peptide from TLR4 in-
hibits TLR4 but does not bind TLR4 TIR, we proposed that the
TLR4 D helix mediates adaptor recruitment (Toshchakov et al.,
2011). Our current study finds that, analogously to TLR4, the
TLR2D helix is an adaptor recruitment site too; we further specify
that this site binds TIRAP. Another interesting analogy is that for
both TLR4 and TLR2, one TIR of the dimer seems to interact with
the other TIR via a large surface formed by AB and BB loops with
an important contribution of the region that is immediately N-ter-
minal to the TIR domain (Figure 7B). We previously proposed
that, in the case of TLR4, this region interacts with the E helix
of the other TIR of the dimer (Toshchakov et al., 2011). At this
time, it is not known whether the mode of interaction of TLR2
co-receptors with TLR2 is similar.
Available mutagenesis data support the importance of TLR2
BB loop and the D helix for TLR2 function (Gautam et al., 2006;
Xiong et al., 2012). A rare SNP allele (rs5743708), which results
in R753Q replacement in the middle of the D helix of TLR2 TIR
(Figure 7A), is associated with higher susceptibility to infections
caused by several bacterial and viral pathogens (Lorenz et al.,
2000; Ogus et al., 2004; Schro¨der et al., 2005).
Studies of 2R9 binding to putative components of the primary
TLR2 signaling complex indicated this peptide specifically binds
TIRAP (Figure 3). FLIM measurements suggested that the
apparent 2R9/TIRAP binding affinity measured directly in cells
is approximately ten times higher than that for the 2R9/TLR1 or
2R9/MyD88 pairs (Figure 3C). The FP experiments using recom-
binant TIRAP confirmed the high binding affinity with KD of
40 nM for the 2R9/TIRAP pair. Although the FP studies also de-
tected binding of 2R9 to BSA (Figure 3F), 2R9 binds albumin with
Figure 6. 2R9 Suppresses PR8-Induced Cytokine Secretion by Macrophages and Improves Survival in a Mouse Model of Influenza
(A–C) Primary peritoneal macrophages obtained from C57BL/6J WT (black columns) or MyD88-deficient (open columns) female mice were kept in cell culture
overnight and challenged with PR8 at 1 MOI for 2 hr. Cytokine content was measured in supernatants 24 hr post-infection.
(D) Survival of mice infected with PR8. C57BL/6J female mice received intranasal inoculate of PR8 (7,500 TCID50; LD90), on day ‘‘0.’’ Starting from day 2, the
mice received 2R9, CP, Eritoran (E5564), or vehicle once daily for the course of 5 successive days. Peptides were administered i.p. at the dose 200 nmol. Eritoran
was administered i.v. at the dose 200 mg (Shirey et al., 2013).
Numerical data are presented as means ± SEM.
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the affinity that is 40 times lower than TIRAP (Figure 3F). Albu-
min is the most abundant serum protein that has several multi-
faceted binding sites capable of binding a range of small and
medium size molecules (Ghuman et al., 2005). Binding to albu-
min significantly improves circulatory half-life of protein- and
peptide-based drugs (Kratz, 2008; Sleep et al., 2013). Improving
the pharmaceutical properties of drug candidates through engi-
neering of molecules with enhanced binding to albumin has
become an established strategy in drug development (Larsen
et al., 2001; Sleep et al., 2013). The observed ratio of affinities
of 2R9 binding to TIRAP versus albumin together with the high
2R9 dose required for TLR inhibitory effect in cells and in vivo
suggest that a significant portion of total 2R9 in the system is
likely bound to albumin under conditions of our in vitro and in vivo
experiments and is thus protected from proteolysis. Although
additional studies are required to elucidate whether reversible
binding to albumin is critical for the observed in vivo efficacy of
2R9, it is likely so. The observed 2R9/TIRAP binding affinity is
very high compared to previously reported interaction of TIRAP
with the viral Bcl-like protein A46 (apparent KD of 1.5 mM) (Oda
et al., 2011). This study, however, failed to measure TIRAP bind-
ing with the TLR4-inhibitory peptide VIPER that is derived from
A46 (Lysakova-Devine et al., 2010; Oda et al., 2011). A separate
SPR study of IL-17RA binding to the CC-loop decoy peptide
from the SEFIR domain of NF-kB activator 1 reported a very
high KD value of 117 mM (Liu et al., 2011).
2R9 blocked TLR2, TLR4, TLR7, and TLR9 but not TLR3 or
TNF-a-mediated signaling. Such a specificity profile agrees
with the notion that this peptide binds TIRAP and precludes
TIRAP interactions with TLR TIR domains. Although TIRAP de-
pendency of TLR7 signaling was not reported previously, our
data suggest that, analogously to TLR9-mediated response,
the TLR7-mediated activation of iBMDM strongly depends on
TIRAP (Figures 4A and 4B). In accordance with these data, the
TIRAP-targeting peptide, 2R9, potently inhibited TLR7 in cells
and in vivo (Figures 4 and 5). The possibility that, in addition to
TIRAP, 2R9 binds other TIR domain proteins, so that the
observed functionality of this peptide is due to targeting of
several TIR domains, cannot be excluded at this time. Particu-
larly, the binding of 2R9 to TLR4 (Figures S5C–S5F) likely ac-
counts for inhibition of LPS-induced cytokines in MyD88- and
TIRAP-deficient cells (Figures 4C and 4D) and, also, increases
the potency of TLR4 inhibition by 2R9 in WT cells. A similar
mechanism of targeting several TIR domains might also play a
role in the inhibition of TLR7 by 2R9 because our data suggest
that, in addition to strong binding to TIRAP, 2R9 directly binds
the TIR of TLR7, albeit with apparent TLR7 binding affinity that
is approximately ten times less. Whether or not this secondary
binding to TLR7 TIR is important for 2R9 activity in vivo remains
to be elucidated.
2R9 also potently suppressed systemic cytokine activation
induced in live animals by a synthetic TLR2 agonist. 2R9 blocked
TLR2-mediated cytokine production more potently than TR6, a
TIRAP-derived peptide that inhibits TLR4 and TLR2 and binds
MyD88 (Couture et al., 2012; Piao et al., 2013a). The in vivo effi-
cacy of 2R9 is confirmed by its effect on TLR7-induced systemic
cytokine levels (Figures 5D–5F).
Influenza virus, a single-stranded RNA virus, is sensed by a
number of pattern recognition receptors, although TLR7 appears
to play the primary role in mice (Diebold et al., 2004; Kawai and
Akira, 2011; Lund et al., 2004). Accordingly, 2R9, which potently
blocks TLR7, significantly inhibited the MyD88-dependent cyto-
kine production by PR8-infected macrophages in cell-culture
experiments (Figures 6A–6C). 2R9 less potently affected the
PR8-induced IFN-b because of significant contribution of RLRs
to induction of this gene.
TLR4 and TLR2 activation by endogenous, damage-associ-
atedmolecules secondary to acute lung injury, caused by a path-
ogen or chemically induced, significantly contributes to severity
of influenza (Imai et al., 2008; Shirey et al., 2013). The potent
TLR4 antagonist, Eritoran, protected mice from PR8 infection;
however, TLR2/ mice could not be protected with Eritoran,
indicating complexity of TLR roles in influenza and Eritoran-
mediated protection. Therefore, a TLR antagonist that is multi-
specific and blocks a set of TLRs, including TLR2 and TLR4,
may have distinct advantages for treatment of systemic inflam-
mation in infectious disease, compared to a monospecific TLR
antagonist. Our data demonstrate that 2R9, a cell-permeating
decoy peptide, that inhibits TLR7, TLR4, and TLR2, indeed pro-
vided robust protection against PR8-induced lethality in mice,
equivalently to Eritoran (Figure 6D). The broad specificity of TLR
inhibition by 2R9 also suggests this peptide might be effective
for modulation of inflammation caused by bacterial and/or viral
co-infections.
Excessive inflammatory response elicited by lethal pathogens
is the prevailingmechanistic cause of lethality in acute infections.
Nonetheless, therapeutic interventions to reduce inflammatory
response to pathogens, so that the injurious component is
mitigated, yet the remaining response is adequate to activate
anti-microbial defenses, are not developed sufficiently, despite
significant efforts. Our study has resulted in the identification of
a peptide that blocks several TLRs. We have demonstrated
that this D-helix peptide, 2R9, predominantly targets TIRAP, is
effective in vivo, and protects mice from deadly PR8 infection.
Importantly, potency and biological stability of the inhibitor is
amenable to improvement in a number of rational approaches,
including peptidomimicry, to develop more effective therapeu-
tics. Although the screening of peptide library derived from
an interaction domain of TLR2 has resulted in identification of
a potent TLR inhibitor in this study; further studies will be neces-
sary to determine whether this decoy peptide approach is
Figure 7. Position of Regions Represented by TLR2 Peptides
(A) D helix is located on the side opposite to 2R1. Polymorphic R753 is shown
in yellow. Leu752 (black) has surface exposure less than 2%.
(B) Presumable dimerization interface of TLR2.
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generally applicable to targeting the intracellular signaling events
downstream of activated receptors and search for signaling in-
hibitors and therapeutic leads.
EXPERIMENTAL PROCEDURES
Animals, Cells, and Cell Culture
C57BL/6J WT and MyD88-deficient mice were obtained from the Jackson
Laboratory. Harvesting, culturing, and stimulation of peritoneal macrophages
were described previously (Toshchakov et al., 2005). THP-1 cells were differ-
entiated by incubation in the presence of 10 nM phorbol 12-myristate 13-ace-
tate (PMA) in 10%FCSRPMI-1640 for 3 days. TLR agonists, P3C, P2C, FSL-1,
R848, ODN1668, and high-molecular-weight poly(I:C) were purchased from
Invivogen. Escherichia coli K235 LPS was phenol-purified. Mouse rTNF was
purchased from BioLegend.
PR8 Infection
The mouse-adapted H1N1 A/PR/8/34 strain of influenza virus (PR8) was ob-
tained from ATCC and propagated as previously described (Shirey et al.,
2013). Peritoneal macrophages were infected at MOI = 1. After a 2-hr incuba-
tion in the presence of PR8, cells were washed with PBS and incubated
in RPMI supplemented with 2% FCS, without or with a decoy peptide.
C57BL/6J female mice were infected with 7,500 TCID50 (LD90) of PR8 intrana-
sally. Two days post-inoculation, mice received a 5-day course of 2R9 or
2R8 as a single i.p. administration daily at the dose of 200 nmol. Eritoran
(200 mg/mouse), administered intravenously (i.v.) daily for 5 days starting on
day two, was included as a positive control (Shirey et al., 2013). Survival
was monitored for 14 days. All animal experiments were conducted with
approval from the University of Maryland, Baltimore Institutional Animal Care
and Use Committee.
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